| AcelRx Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Co.'s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. Co.'s nafamostat product candidates include Niyad, which is being developed as a regional anticoagulant for injection into the extracorporeal circuit; and LTX-608, which is Co.'s proprietary nafamostat formulation for direct IV infusion. Co.'s pre-filled syringe product candidates include Fedsyra, which is an ephedrine pre-filled syringe; and the phenylephrine pre-filled syringe. The ACRX YTD return is shown above.
The YTD Return on the ACRX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ACRX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ACRX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.